Sequenom To End Shareholder Suits With $45M Deal
Sequenom Inc. has reached a deal worth roughly $45 million to resolve a slew of shareholder suits accusing the genetic analysis company of inflating its stock price with hype about a...To view the full article, register now.
Already a subscriber? Click here to view full article